Ascletis Pharma Inc.

Investors

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
2026-10-06
Voluntary Announcement - Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026
2026-10-02
Interim Report 2026
2026-09-29
Voluntary Announcement - Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis
2026-09-29
Voluntary Announcement - Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
2026-09-08
Voluntary Announcement - Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
2026-09-07
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2026
2026-09-03
2026 Interim Results
2026-08-31
Voluntary Announcement - Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
2026-08-30
Profit Warning
2026-08-21

1

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备11050387号-1 Cookie Settings